“In light of the ongoing COVID-19 pandemic, a number of pharma companies have postponed new study starts and have paused enrollment/screening in their clinical trials. However, companies that have completed an analysis of their trial data are sticking to the timeline of reporting the results,” notes the author of today’s article, who proceeds to take a look at three biotech/pharma companies that are still expected to report clinical trial results this quarter. For these three companies – and their potential catalysts due this quarter – CLICK HERE.
3 Biotech/Pharma Stocks With Potential Clinical Trial Catalysts This Quarter
- by Bob Mitchell
Tags:Biotech StocksCOVID-19 PandemicInvestingPharma CompaniesPharma StocksStock MarketstocksTrial Goals